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Summary
The incidence of oropharyngeal cancers is rising
worldwide in both nonsmokers and nondrinkers.
Epidemiology studies suggest a strong association
between human papillomavirus (HPV) 16 infection,
changing sexual behavior and cancer development.
Despite initial presentation with locally advanced
disease and poorly differentiated histology, HPV-
associated oropharyngeal carcinoma is associated
with a good prognosis because its response to
chemotherapy and radiation. Clinicians should
be aware of the risk of oropharyngeal cancer in
young people to avoid unnecessary delay in diag-
nosis and treatment. A history of oral sex should
be elicited in young patients with enlarged neck
nodes and/or tonsillar masses.
Introduction
Oropharyngeal carcinoma prevalence is rising
steadily in the United States and Western Europe
despite successful effort to control smoking and
drinking.1–3 A report from the Surveillance,
Epidemiology, and End Results (SEER) database
demonstrated a statistically significant increase
of oropharyngeal cancers affecting young people
between the age of 20- and 44-years old.4 There
was a strong association between human papilloma-
virus (HPV) 16 and oropharyngeal malignancy
which affected all ethnic groups in the US.5,6
A recent public health study projects an increased
incidence of HPV infection of epidemic proportion
in young adults because of changing sexual habits.7
Thus, the cost to society would be unacceptable
in terms of loss of life because of the expected rise
in pharyngeal malignancy.8 It is important for pri-
mary care physicians to recognize this new clinical
entity to avoid delays in diagnosis that can lead to
poorer outcomes.9 This review describes the mech-
anism of HPV infection in oropharyngeal cancers,
current treatment options and prognosis following
treatment.
Materials and methods
This systematic review was designed to investigate
the rising incidence of oropharyngeal carcinoma
in the young. A search was undertaken from 1990
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when the first cases of HPV 16 DNA integration
into the tonsillar carcinoma genome was reported,
until 2009. Searches were based on PubMed,
Embase and Google Scholar electronic databases.
The following terms were explored and used for
each database search: oropharyngeal carcinoma,
young, HPV 16, treatment and prognosis. Searches
for additional publications were conducted using
the references lists of applicable articles.
Epidemiology of HPV 16 infection
and oropharyngeal cancer
Tobacco and alcohol abuse used to be the strongest
predictors of developing oropharyngeal carcinoma
in old individuals (over 60).10,11 Most patients pre-
sented with locally advanced stages at diagnosis.
Despite aggressive treatment with postoperative
radiation or chemoradiation, survival remained
poor because of the high rates of recurrences12–19
(Table 1). Recent epidemiologic studies revealed
an increased incidence of oropharyngeal carcinoma
in young people with no smoking or drinking
history.1,20,21
A viral etiology for oropharyngeal cancer similar
to cervical cancer has been postulated as sexual
partners of patients with HPV infection developed
a higher risk of second head and neck primaries.20
Recently, HPV 16 DNA with identical sequences
was isolated in tonsillar carcinoma of two non-
smoking, non-drinking couples highlighting the
infectious nature of the disease.22 Young patients
with multiple sex partners and oral–genital sex are
at an increased risk of developing HPV-associated
oropharyngeal cancers with HPV 16 as the predom-
inant type.23 Polymerase chain reaction (PCR)
has demonstrated HPV DNA presence in cancer
cells but not in the adjacent normal epithelium.
Among all the head and neck sites, tonsillar carci-
noma had the highest prevalence of HPV 16 infec-
tion suggesting that the virus had a special affinity
for tonsillar epithelium.24,25 There was a strong
correlation between the patient age and the preva-
lence of HPV 16 in the biopsy specimen. El Moffty
et al.26 reported a 91% rate of HPV 16 infection
in tonsillar carcinoma of patients <40- years old.
The prevalence of HPV 16 DNA diagnosed in ton-
sillar carcinoma specimens by in situ hybridization
or PCR ranged from 50% to 84% for patients
with median age in the fifties.27–32 For patients
with median age in the sixties, HPV infection rate
ranged from 21% to 46%. It is currently unclear
why younger patients are more at risk for HPV
16-associated oropharyngeal cancer. One possible
explanation is the vulnerability of the tonsillar epi-
thelium to HPV infection as observed in cervical
carcinoma.33 In the US, oral sex begins early
among middle and high school students exposing
their oropharynx to HPV virus infection.34,35
Among students who practiced oral sex, up to
two-thirds had more than one partner.34 Condoms
are seldom used for oral sex.36 Thus, viral-induced
oropharyngeal carcinoma may reach epidemic pro-
portion because of the change in sexual behavior.
As an illustration of this phenomenon, the propor-
tion of HPV 16-associated tonsillar carcinoma
has steadily increased in Sweden with rates of
68%, 77% and 93% for the periods of 2000–
2002, 2003–2005 and 2006–2007, respectively
(P< 0.0001).27 The prevalence of HPV 16 negative
tumors also decreased in the same period. Multiple
studies have corroborated the relationship between
sexual behavior, risk of developing HPV infection
and subsequent development of oropharyngeal
cancer in young patients which is now of epidemic
proportion worldwide.3,4,37–41
Postulated mechanism of HPV 16
infection and oropharyngeal cancer
The mechanism of HPV 16 infection leading to
the development of oropharyngeal carcinoma is
unclear. HPV is a small double-stranded virus with
special affinity for the skin and mucosa. Transfection
of human primary epithelial cell lines derived
from normal tonsils with HPV 16 produced immortal
cell lines.42 All transformed cells contained abnor-
mal chromosomal abnormalities (breakage, conden-
sation, dicentric and acentric chromosomes). Viral
DNA was integrated into the genome of transfected
cells with a particular predilection for chromosome
7q31 and 9q34. Even though transformed cells
retained the morphology of normal tonsillar cells,
Table 1 Survival of locally advanced head and neck
cancer following post-operative radiotherapy or chemor-
adiation in randomized studies
Study Site Survival (%) (years)
Kramer et al.11 All sites 36% (5)
Denis et al.12 Oropharynx 22% (5)
Fallai et al.13 Oropharynx 40% (5)
Staar et al.14 Oropharynx 60% (2)
Semrau et al.15 Oropharynx 22.9% (5)
Bensadoun et al.16 Oropharynx 54% (2)
Posner et al.17 All sites 62% (3)
Brizel et al.18 All sites 55% (3)
Adelstein et al.19 All sites 57% (3)
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they were poorly differentiated with less cytokeratin
expression.42 Integration of viral DNA in host chro-
mosome 7q31 induced alteration of E2 gene
which normally downregulates E6 and E7 genes.43
Tonsillar carcinoma cells infected with HPV 16
demonstrated high expression of E6 and E7 messen-
ger RNA.44 As a result, oncoproteins E6 and E7
accumulated inside infected cells.45 Oncoprotein
E6 induced the degradation of tumor suppressor
p53 and reduced the infected cell ability to undergo
apoptosis. Oncoprotein E7 degraded the retinoblas-
toma protein (pRb) and prevented it from inhibiting
of the cell cycle leading to uncontrolled cell prolif-
eration. Consistent with this hypothesis, tonsillar
carcinoma associated with HPV 16 demonstrated
downregulation of pRB and cyclin D1.46 Inhibition
of E6 and E7 by short hair-pin RNA retroviruses
induced the functional restoration of p53 and pRB
functions in HPV 16-associated oropharyngeal
squamous cell lines.47 However, even though the
overexpression of oncoproteins E6 and E7 are essen-
tial steps for malignant transformation because of
continued cellular proliferation, it remains unclear
how other genes may interact with these oncopro-
teins to transform the infected cells into an immortal
state. A potential synergistic role for ras oncogene
has been suggested with E6 and E7 in transgenic
mice to produce ear and mouth tumors, but more
work needs to be done to elucidate the mechanism
of cancerization.48
The P16 protein (p16) is a cyclin-dependent
kinase (CDK) inhibitor that is normally inhibited
by pRB. Loss of pRB function by HPV 16 virus incor-
poration into host genome leads to overexpression
of p16.49,50 Increased p16 expression is often asso-
ciated with poorly differentiated tumor and locally
advanced (T4,N2-3) HPV-associated oropharyngeal
carcinoma at diagnosis.50
Paradoxically, despite advanced stages at diagno-
sis, overexpression of P16 is a strong predictor
for survival advantages independent of TNM staging
for HPV-associated oropharyngeal carcinoma.50–60
There is a strong correlation between P16 expres-
sion and response of oropharyngeal tumors to
radiotherapy.In a prospective study of 156 head
and neck cancers treated with radiotherapy alone,
35 patients were reported to have increased P16
in the biopsy specimen.57 Twenty-four of these
patients (69%) had oropharyngeal cancer. The
5-year loco-regional control was 58% and 28% for
p16 positive and negative tumors, respectively
(P=0.0005). Corresponding values for survival
were 62% and 26% (P=0.0003), respectively.
Increased radiosensitivity of p16 positive tumors
was also corroborated in another study. Complete
response rate to radiotherapy alone was respectively
86% and 33% for high and low expression p16
tonsillar cancers.53 P16 is also a biomarker for
tumor chemosensitivity. Kumar et al.52 reported
50 patients with locally advanced oropharyngeal
cancer treated by induction chemotherapy fol-
lowed by chemoradiation and postoperative radio-
therapy for responders and non-responders,
respectively. There was a statistically significant
correlation between p16 expression and response
to chemotherapy which translated into better
survival for patients with high P16 expression.52
Thus, survival for patients with locally advanced
oropharyngeal cancer and high P16 expression
was significantly increased with chemoradiation
because of the tumor radio- and chemosensitiv-
ity.55,56 Nichols et al.56 reported a 3-year survival
of 89% and 65% for P16 positive and negative oro-
pharyngeal tumors, respectively following concur-
rent chemotherapy and radiotherapy. Other studies
have also corroborated the excellent survival asso-
ciated with high expression of P16 following
chemoradiation for oropharyngeal cancers.52,55
One possible explanation for the radiosensitivity
of HPV 16-associated oropharyngeal tumors is the
upregulation of RBBP4, a gene that has been shown
to induce radiosensitivity, in head and neck cancer
cell lines infected with HPV 16.61 In addition to a
favorable response rate to treatment, patients with
HPV-associated oropharyngeal cancers also have a
very low rate of second malignancies and distant
metastases which may account for their long-term
disease-free survival.62 Both long-term survival
and disease-free survival correlated with viral load.
The 4-year survival was respectively 64% and 100%
for viral copies less than 50 and more than 500.63
Other studies also corroborated the beneficial effect
of increased viral load in the tumor specimen
suggesting that the biology of HPV-positive tumors
is less aggressive compared to HPV-negative
tumors.29,54
The molecular biology of HPV 16-associated
oropharyngeal carcinoma is markedly different
from HPV-negative oropharyngeal carcinoma.
HPV-negative oropharyngeal carcinoma occurs in
older individuals with a long history of smoking
and drinking.64 Thus, they are at risk of field cancer-
ization in contrast to HPV 16 which has a special
predilection for tonsillar crypts.
HPV-negative tonsillar carcinoma are associated
with a high expression of p53 and cyclin D1, which
is minimal or absent in HPV-positive tumors.45,65
HPV-negative tumors are also associated with
well-differentiated squamous histology in contrast
to the poorly differentiated or basaloid histology
of HPV-positive tumors.45 Epidermal growth fac-
tor receptor (EGFR) is strongly expressed in
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HPV-negative tumor and is absent or minimally
expressed in HPV-positive Tumors.49 High expres-
sion of EGFR is usually associated with a poor prog-
nosis because of high loco-regional recurrences
rates and distant metastases.66,67 Licitra et al.59 sug-
gested that low EGFR levels may be the cause for
improved survival in HPV-positive oropharyngeal
cancers treated with surgery alone. However,
other biomarkers for poor survival such as survivin
are also elevated in HPV-negative oropharyngeal
cancers and may account for the poor prognosis
observed.68 HPV-positive and negative oropharyn-
geal tumors are also characterized by distinct
genetic signatures.69,70 Chromosomal alterations
and amplifications are more frequent in HPV-
negative tumors and are associated with worse
survival.69 HPV-negative and positive tumors have
distinct sets of upregulated and downregulated
genes involved in cell proliferation, transcription,
apoptosis and DNA repair.70
Table 2 summarizes characteristics of HPV
16-positive and -negative oropharyngeal tumors.
Table 3 summarizes survival difference between
HPV-positive and negative oropharyngeal cancers.
Management of HPV 16-associated
oropharyngeal carcinoma
Most patients with HPV 16-associated oropharyn-
geal carcinoma present with locally advanced
disease at diagnosis.52,54 Resectable tumors can be
treated with either surgery followed by postopera-
tive radiotherapy or concurrent chemoradiation
with similar outcome.72 Unresectable disease are
usually treated with concurrent chemoradiation
because of superior survival rates compared to
radiotherapy alone.12–19 However, survival is usu-
ally poor because of high rates of loco-regional
recurrences and distant metastases. Three-year
survival rates ranged from 55% to 62% and
decreased to 22% at 5 years. The observed low sur-
vival rate was similar to patients with HPV
16-negative tumors (Table 3) and reflected a differ-
ent patient population consisting of older, smokers
and drinkers, and most likely EGFR positive and P16
negative subjects. HPV oropharyngeal cancers
represent a distinct population of patients with
excellent survival (5 year survival in the 80 percent
range) regardless of the type treatment.
Given the fact that most HPV-positive patients
are young, treatment selection should take into con-
sideration the mortality and morbidity associated
with the selected treatment. Surgery of the orophar-
ynx is associated with significant alteration of
Table 2 Characteristic differences between HPV 16-positive and -negative oropharyngeal cancers
Positive Negative
Age Younger (30–50s) Older (60–70s)
Life style Oral sex Smoking, drinking
Field cancerization No Yes
Predilection Tonsils No
Histology Poorly differentiated Basaloid Well differentiated
Biomarkers P 16 EGFR, p53, cyclin D, survivin
Chromosomal alterations Less frequent Frequent
Prognosis Excellent Poor
Distant metastases Rare Frequent
Second malignancies Rare Frequent
Table 3 Survival difference between HPV 16-positive
and -negative oropharyngeal cancers
Survival
Study Patient
No
Treatment
type
HPV+
(%)
(years)
HPV
(%)
(years)
Chung et al.28 46 CRT 86 (5) 35 (5)
Hafkamp et al.46 77 NS 69 (5) 31 (5)
Kumar et al.52 50 CRT 80 (5) 40 (5)
Weinberger et al.54 107 RT 79 (5) 20 (5)
PostopRT
Nichols et al.56 44 CRT 89 (3) 69 (3)
Lassen et al.57 156 RT 62 (5) 26 (5)
Reimers et al.60 97 S 73 (5) 63 (5)
RT
CRT
Fakry et al.71 62 CRT 78 (5) 50 (5)
CRT, chemoradiation; NS, not specified; RT, radiotherapy;
S, surgery; postopRT, postoperative radiation.
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speech and swallow because of resection of criti-
cal muscles essential for these functions.73,74
Chemoradiation offers several advantages including
anatomic organ preservation and speech conserva-
tion. In addition, surgery is associated with a higher
mortality rate compared to radiotherapy.75 Mortality
rates and serious complications were 3.2% and
23%, respectively for surgery compared to 0.8%
and 6% for radiotherapy.75 Thus, concurrent che-
moradiation is usually selected in most institutions
for locally advanced oropharyngeal cancers.
However, with early detection, HPV-positive
patients may not require the combined modality as
surgery or radiotherapy alone provide excellent
survival with less morbidity.75,76 Patients with HPV
associated oropharyngeal cancers are often initially
misdiagnosed with upper aero-digestive infections
because of their young age and lack of information
by the primary care physicians about this clinical
entity. These patients are usually treated with pro-
longed courses of antibiotics thus delaying their
cancer diagnosis.77 Oropharyngeal cancer patients
with early diagnosis have been shown to have less
advanced stages at diagnosis, resulting in improved
survival.78 Treatment with radiotherapy alone for
early stages instead of concurrent chemoradiation
for locally advanced diseases is less costly for
society.
It is estimated that for each head and neck can-
cer patient treated with radiotherapy alone, 10 000
dollars is saved compared to chemoradiation due to
the cost of chemotherapy and radiotherapy- related
complications.79 A history of oral sex should be
obtained in sexually active young people with a
sore throat and should raise a red flag for a possible
underlying malignancy. Early referral to Ear,
Nose and Throat surgeons will decrease treatment
morbidity and treatment cost. Thus, primary care
physicians will play a major role in the management
of oropharyngeal cancer. As HPV 16-associated
oropharyngeal cancers carry an excellent prognosis,
new treatment protocols are under consideration
for selection of patients with advanced stages who
may benefit from radiotherapy alone instead of the
combined modality. Patients presenting with small
tumors, high expression of p 16, minimal or absent
EGFR expression and high viral load in the tumor
specimen have excellent survival despite the pres-
ence of neck nodes.29,30,52,54,58,60,63 Patients fitting
these criteria may be enrolled in a protocol study
with radiotherapy alone to decrease treatment
morbidity and to improve quality of life. This treat-
ment approach should be considered experimental
as concurrent chemoradiation or postoperative
radiotherapy remains the standard of care for locally
advanced head and neck cancer.
Prevention of HPV 16 infection
As the mean time between HPV infection and
cancer development is about 12 years, the number
of young adults developing oropharyngeal cancer is
expected to rise steadily in the years to come.80
Vaccination must be started prior to sexual puberty
to be effective as adolescents consider oral sex and
deep kissing as safe alternatives to avoid unwanted
pregnancy and venereal diseases. HPV 16 infection
currently affect all ethnic groups in the US because
of the changing attitude toward sex.5 Vaccination
should target both males and females along with
public education as most adolescents have little
knowledge about the risks involved with sexual
behavior.81,82 Unless physicians take an active
role to educate the public and promote clinical
trials for vaccination, we will witness a tidal wave
of young people with head and neck cancer in the
next decades.
Conclusions
HPV-associated oropharyngeal cancers is a com-
plete clinical entity distinct from the traditional
head and neck cancer that affects young people
and is related to sexual behavior. Despite excellent
prognosis, physicians should refer patients early on
to avoid delay in diagnosis and to reduce treatment
cost and morbidity related to chemoradiation-
induced complications. Vaccination against HPV
16 should be considered in future clinical trials.
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